Heat Shock Protein Gp96 Adjuvant Induces T Cell Responses and Cross-Protection to a Split Influenza Vaccine.

Ying Ju,Hongxia Fan,Jun Liu,Jun Hu,Xinghui Li,Changfei Li,Lizhao Chen,Qiang Gao,George F. Gao,Songdong Meng

DOI: https://doi.org/10.1016/j.vaccine.2014.03.045

IF: 4.169

2014-01-01

Vaccine

Abstract:The commonly used inactivated or split influenza vaccines induce only induce minimal T cell responses and are less effective in preventing heterologous virus infection. Thus, developing cross-protective influenza vaccines against the spread of a new influenza virus is an important strategy against pandemic emergence. Here we demonstrated that immunization with heat shock protein gp96 as adjuvant led to a dramatic increased antigen-specific T cell response to a pandemic H1N1 split vaccine. Notably, gp96 elicited a cross-protective CD8(+) T cell response to the internal conserved viral protein NP. Although the split pH1N1vaccine alone has low cross-protective efficiency, adding gp96 as an adjuvant effectively improved the cross-protection against challenge with a heterologous virus in mice. Our study reveals the novel property of gp96 in boosting the T cell response against conserved epitopes of influenza virus and its potential use as an adjuvant for human pre-pandemic inactivated influenza vaccines against different viral subtypes.